Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil drug-drug interaction study in healthy volunteers
NCT05806567Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belumosudil (3 arms), sponsored by Sanofi. Primary endpoints: Area Under the Curve from Time Zero to Last Measurable Concentration at 15 days and Area Under the Curve from Time Zero to Infinity at 15 days. Started Jul 2022; status: completed.
02
Drugs
belumosudil
Beyond the preview
Go deeper on NCT05806567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806567.